AUTH/3560/9/21: Anonymous health professional complaint about pressure to sign up to diabetes review service (No breach) – Sanofi

📅 2021 | 🖉 Dr Anzal Qurbain
📊

Key facts

Case numberAUTH/3560/9/21
ComplainantAnonymous health professional (described themself as a nurse); non-contactable
CompanySanofi
IssueAlleged pressure/harassment by an account executive to sign up to a diabetes therapy review service
Activity/service“Diabetes Therapy Review Service” (described by Sanofi as a medically led MEGS delivered by a third-party provider)
Applicable Code year2021
Clauses consideredClause 17.2; Clause 17.9
Panel decisionNo breach of Clause 17.2; No breach of Clause 17.9 (No breach overall)
Complaint received26 September 2021
Case completed31 May 2022
AppealNo appeal
SanctionsNone

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

  • An anonymous, non-contactable complainant (describing themself as a nurse) alleged a named Sanofi diabetes representative (account executive) repeatedly asked them to sign up to a diabetes review service despite being told no.
  • The complainant said the request was made “as a favour” and made them feel “pressurised and harassed”.
  • The complainant believed the representative may have been pressured by superiors and said they would not see the representative again.
  • Sanofi investigated by reviewing internal briefing materials and interviewing the account executive and their manager.
  • Sanofi stated the “Diabetes Therapy Review Service” was a medically led MEGS activity delivered by a third party; promotional colleagues (account executives) were briefed not to discuss it and to refer any unsolicited enquiries to an MSL.
⚖️

Outcome

  • No breach of the Code was ruled.
  • No breach of Clause 17.2 (alleged inappropriate conduct / failure to maintain high standards) because the complainant did not establish the allegation on the balance of probabilities.
  • No breach of Clause 17.9 (briefing/training leading to a breach) because there was no evidence the briefing advocated conduct likely to lead to a breach.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training